BioInformant

Your Global Leader in Stem Cell Market Research

Home » Interviews » Page 11

BioInformant's Founder, Cade Hildreth, has interviewed hundreds of key opinion leaders (KOL's) from across the stem cell industry.

Okyanos – Adipose-Derived Stem Cell Treatments with CEO Matt Feshbach

By

Matthew Feshbach, CEO and Co-Founder of Okyanos
Matthew Feshbach, CEO and Co-Founder of Okyanos

Founded in 2011, Okyanos (pronounced “Oh – key – AH – nos”) is an innovative stem cell therapy provider that specializes in treating patients with congestive heart failure (CHF) and other chronic conditions. The literary name Okyanos, the Greek God of the river Okyanos, symbolizes the restoration of blood flow. Okyanos Cell Therapy delivers a mixed population of fat (adipose) derived stem and regenerative cells (ADRCs) using internationally-approved technology to patients with chronic, degenerative conditions.  Okyanos is fully licensed under the Bahamas Stem Cell Therapy and Research Act and adheres to U.S. surgical center standards.  [Read more…]

Role of MSC-Derived Exosomes in Healing the Injured Spinal Cord – Interview with Dr. Askenase

By

MSC Exosomes, Dr. Askenase
Dr. Philip Askenase, Professor at Yale University School of Medicine

This is an interview with Philip Askenase, MD, Professor of Medicine and Pathology at Yale University School of Medicine. Dr. Askenase is an expert in the effector  properties of exosomes who is now beginning to study mesenchymal stem cell (MSC)-derived exosomes and their role in regenerative processes.

Specifically, Dr. Askenase’s new unpublished preliminary work is focused on the role of MSC-derived exosomes in healing the injured spinal cord in rats.

In this interview, we discuss the growing importance of MSC-derived exosomes, including their advantages and applications. We also explore the market potential for stem cell exosomes, as well as companies competing in this emerging market area.

[Read more…]

Setting the Standard in Adipose-Derived Stem Cell Applications

By

Matthew Feshbach, CEO and Co-Founder of Okyanos
Matthew Feshbach, CEO and Co-Founder of Okyanos

This article is part two of my interview with Matthew Feshbach, CEO and Co-Founder of Okyanos (pronounced “Oh – key – AH – nos”). Founded in 2011, Okyanos specializes in treating patients with chronic, degenerative conditions. Located in Freeport, Grand Bahama, just 55 miles from the United States, Okyanos Cell Therapy combines a blend of stem and regenerative cells derived from a patient’s own adipose (fat) tissue.

Treatment is performed in their state-of-the-art surgical center by a team of U.S. licensed medical doctors. Okyanos is also fully licensed under the Bahamas Stem Cell Therapy and Research Act and adheres to U.S. surgical center standards.

Using technology from Cytori Therapeutics, the company offers a highly characterized cellular product that is administered via a robust protocol by a renowned medical team within a world-class facility. It is my opinion, that Okyanos is a company that is setting the standard for others practicing cellular therapy with adipose-derived stem and regenerative cells.

Enjoy this second half of the interview. If you haven’t read it yet, click here to view Part 1. [Read more…]

Interview with Dr. Paul Wotton of Cynata Therapeutics and Previous CEO of Ocata Therapeutics

By

I am honored to release thisCynata Therapeutics interview with Dr. Paul Wotton, who joined Cynata Therapeutics Board of Directors in June, 2016.  He was previously President and CEO of Ocata Therapeutics, Inc. (NASDAQ: OCAT) joining the company in July 2014 and managing it through an all-cash take-over by Astellas Pharma valued at $379 million. Prior to Ocata, Dr. Wotton had served as President and CEO of Antares Pharma Inc. (NASDAQ: ATRS), since October, 2008. Prior to joining Antares, Dr. Wotton was the CEO of Topigen Pharmaceuticals and prior to Topigen, he was the Global Head of Business Development of SkyePharma PLC.

Dr. Wotton is also a member of the board of Vericel Corporation, an American company developing autologous cellular therapies and also past Chairman of the Emerging Companies Advisory Board of BIOTEC Canada.    Dr. Wotton received his Ph.D. in pharmaceutical sciences from the University of Nottingham and an MBA from Kingston Business School.

Enjoy Dr. Wotton’s insights in his interview below. [Read more…]

Use of Placental Tissue Matrix for Regenerative Medicine Applications

By

Neo Matrix MedicalI am honored to release this interview with Bobby Ardila, V.P. of International Medical Communications for Neo Matrix, LLC. Neo Matrix is a newly formed cell therapy company serving the U.S.A. and South American markets.  In this interview, we explore the company’s use of a placental tissue matrix component for regenerative medicine applications.

[Read more…]

BioInformant's World-Class Clients